fda (cder): generic development and bridging global regulations
Published Streamed 2 years ago • 521 plays • Length 59:10Download video MP4
Download video MP3
Similar videos
-
16:56
global generic drug landscape
-
1:00:20
fda office of generic drugs and advancing generic drug development
-
19:58
cder industry assistance resources (13of15) redi – may 29-30, 2019
-
25:59
fda’s inactive ingredient database (iid) (3of35) complex generics – sep. 25-26, 2019
-
19:16
pharmaceutical quality policies: what you need to know (10/15) global quality
-
24:20
overview of the quality system regulation
-
9:20
considerations for establishing q1/q2 sameness of complex formulations (10of39) complex generics '18
-
52:07
common cmc (quality) issues and how to avoid them part ii (13of16) generic drugs forum 2020
-
55:15
harmonization and global efforts for safe and effective generic drugs
-
14:52
postmarketing safety and surveillance of generic drugs update
-
2:11
the generic drug approval process
-
50:27
model-integrated evidence for generic drug development – session 1b
-
25:07
cder small business and industry assistance overview (12of14) redi 2018
-
8:05:24
advancing generic drugs development: translating science to approval 2023 - day 1
-
19:10
product-specific guidances for complex generic drugs
-
20:06
major issues and facilities in drug master files (9/15) global quality
-
9:26
introduction to “the anda review pathway” (11/28) generic drugs forum 2017
-
3:41
fda cder regulatory science: patient-focused drug development
-
47:42
generic combination products: assessment and regulatory update (14of16) gdf 2020
-
1:11
about fda’s regulatory science program
-
23:10
complex product development (3of28) generic drugs forum – apr. 3-4, 2019
-
37:20
importance of global harmonization for patient access to generic drugs